Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
Net Margin
Crinetics Pharmaceuticals Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
|
2.9B USD |
-43 191%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
336.1B USD |
7%
|
|
| US |
|
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 848%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
164.8B USD |
17%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
144.7B USD |
21%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.7B USD |
-9%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
129.7B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.9B USD |
32%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Crinetics Pharmaceuticals Inc
Glance View
In the intricate world of biotechnology, Crinetics Pharmaceuticals Inc. emerges as a keen innovator dedicated to the pursuit of novel therapeutics for endocrine disorders. Established with a mission to harness scientific curiosity into tangible medical solutions, Crinetics focuses on developing oral, small-molecule drugs designed to offer superior treatment alternatives for conditions that involve hormonal imbalances. The company's journey began with a deep dive into endocrine biology, aiming to address complex diseases that are underserved by current therapies. By capitalizing on its proprietary expertise in drug discovery and translational research, Crinetics has carved out a niche in developing non-invasive treatments that uniquely target peptide hormones and their receptors. Crinetics' business model hinges on a meticulous research and development pipeline, pushing its innovation from the laboratory into the clinical trial stage. With a keen eye on niche markets, the company leverages its scientific advances to design drugs that can be easily administered and are cost-effective compared to traditional treatments. The fundamental revenue drivers for Crinetics include partnerships and collaborations with larger pharmaceutical firms, which help it scale and market its pioneering therapies. As its drug candidates advance through the phases of development, the promise of royalty and milestone payments from these collaborations provides a crucial financial lifeline, driving the company closer to its ultimate goal of delivering life-changing therapies to patients worldwide.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Crinetics Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -43 191.1%.
You don't have any saved screeners yet